Immune checkpoint inhibitor colitis, a rising issue in targeted cancer therapy era: A literature review

• Published in: Romanian Journal of Internal Medicine Vol. 62; no. 3; pp. 219 - 230
• Main Authors: Adiwinata, Randy, Tandarto, Kevin, Tanadi, Caroline, Waleleng, Bradley Jimmy, Haroen, Harlinda, Rotty, Linda, Gosal, Fandy, Rotty, Luciana, Hendratta, Cecilia, Lasut, Pearla, Winarta, Jeanne, Waleleng, Andrew, Simadibrata, Paulus, Simadibrata, Marcellus
• Format: Journal Article
• Language: English
• Published: Germany Sciendo 01-09-2024
• Subjects: colitis; Colitis - chemically induced; enterocolitis; Humans; immune checkpoint inhibitors; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; immunotherapy; Immunotherapy - adverse effects; Neoplasms - drug therapy; Neoplasms - immunology; review; Immune checkpoint inhibitors; Colitis; Review; Enterocolitis; Immunotherapy
• ISSN: 2501-062X
• DOI: 10.2478/rjim-2024-0015

Research advances in the oncology treatment field have led to the widespread use of immunotherapy. The usage of immune checkpoint inhibitor (ICI) has improved the survival of cancer patients with metastases. This has also led to the rapidly expanding indications for ICI use. However, ICI usage may lead to toxicity, which may be immune-related, in different organ-specific targets. The immune-related adverse events (irAEs) of ICI may lead to increased morbidity, decreased quality of life, and early termination of ICI. The clinical manifestations of irAEs in the gastrointestinal system are variable, ranging from self-limited to life-threatening or fatal events. In this review article, we would like to focus on discussing ICI-induced colitis, which is one of the most common ICI irAEs in the gastrointestinal tract.